The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

I. Interstitial/parenchymal lung disease

I.au Amiodarone pulmonary toxicity - Amiodarone lung

I. Interstitial/parenchymal lung disease

I.ay Chronic pneumonitis

I. Interstitial/parenchymal lung disease

I.az Unilateral interstitial lung disease

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.m Postoperative ARDS

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.c Hemoptysis

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.k Airway pigmentation (black, bluish, petechial)

XLIII. Airway involvement

XLIII.ab Cough (lone)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a Angioedema (may cause UAO, asphyxia and death)

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLV. Pleural and/or pericardial involvement

XLV.u The apical cap

XLVI. Pulmonary vasculopathy

XLVI.a Pulmonary embolism - Venous thrombosis/thromboembolism

XLVI. Pulmonary vasculopathy

XLVI.i Acute pulmonary hypertension

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ai Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.s Systemic inflammatory response

L. Miscellaneous

L.c Pleuritic chest pain

L. Miscellaneous

L.g Bluish, pseudocyanotic skin discoloration

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.f Takotsubo (stress) cardiomyopathy

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.o Cardiovascular collapse - Cardiogenic shock - Hypotension

LI. Cardiovascular involvement / toxicity

LI.q QTc prolongation

LI. Cardiovascular involvement / toxicity

LI.v Torsades de pointe

LI. Cardiovascular involvement / toxicity

LI.ah Coronary vasospasm - Vasospastic angina

LI. Cardiovascular involvement / toxicity

LI.aw Heart failure (thyrotoxicosis-, thyroid storm-mediated)

LIV. Pulmonary physiology - PFTs

LIV.g Platypnea-orthodeoxia

LV. Imaging

LV.b Imaging: Ground-glass opacities (GGO) / shadowing

LV. Imaging

LV.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

LV. Imaging

LV.j Imaging: Wandering (migratory) pulmonary opacities

LV. Imaging

LV.n Imaging: Intralobular septal thickening - Crazy paving

LV. Imaging

LV.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

LV. Imaging

LV.w Imaging: Lung nodule or nodules

LV. Imaging

LV.x Imaging: Waxing and waning nodules

LV. Imaging

LV.ab Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.ba Imaging: Asymmetrical, predominantly unilateral involvement

LV. Imaging

LV.bb Imaging: Solitary pulmonary nodule

LV. Imaging

LV.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

LV. Imaging

LV.bt Imaging: A pattern consistent with pleuroparenchymal fibroelastosis

LV. Imaging

LV.bv Imaging: A subsolid lung nodule or nodules

LV. Imaging

LV.cb Imaging: Disseminated patchy pulmonary opacities

LVI. Distinctive patterns - 'Eye-catchers'

LVI.b Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT

LVI. Distinctive patterns - 'Eye-catchers'

LVI.j Eye-catcher: Avid lung uptake on 18F-PET-CT

LVI. Distinctive patterns - 'Eye-catchers'

LVI.k Eye-catcher: An electron-dense liver on unenhanced CT

LVI. Distinctive patterns - 'Eye-catchers'

LVI.p Eye-catcher: An electron-dense ('white') thyroid

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.b BAL: An excess proportion of neutrophils

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.c BAL: An excess proportion of eosinophils

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.e BAL: Stainable iron in macrophages

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.f BAL: Foamy macrophages

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.m BAL: A normal cell differential

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.p BAL: Lamellar bodies in AM on EM

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

LVIII. Pathology

LVIII.c Path: Acute eosinophilic pneumonia pattern (see also under XVIb)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.k Path: Desquamative interstitial pneumonia (DIP-pattern)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.r Path: Alveolar hemorrhage (see also IIIa)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern

LVIII. Pathology

LVIII.w Path: Pulmonary fibrosis (UIP-pattern)

LVIII. Pathology

LVIII.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

LVIII. Pathology

LVIII.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

LVIII. Pathology

LVIII.ag Path: Histiocytic proliferation

LVIII. Pathology

LVIII.aj Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

LVIII. Pathology

LVIII.ak Path: Smudged geographic necrosis

LVIII. Pathology

LVIII.bm Path: Pleuritis, pleural fibrosis

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

XLIII. Airway involvement

XLIII.c Exacerbation or deterioration of preexisting asthma

XLIII. Airway involvement

XLIII.d Exacerbation or deterioration of preexisting COPD

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLVI. Pulmonary vasculopathy

XLVI.v Worsening of preexisting PHTn

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.aa Subclinical ANA positivity

L. Miscellaneous

L.o Death following exposure or poisoning

L. Miscellaneous

L.ac Refractoriness to epineprine in case of anaphylaxis

LI. Cardiovascular involvement / toxicity

LI.o Cardiovascular collapse - Cardiogenic shock - Hypotension

LI. Cardiovascular involvement / toxicity

LI.u Cardiac- cardiorespiratory/pulmonary arrest

LI. Cardiovascular involvement / toxicity

LI.ah Coronary vasospasm - Vasospastic angina

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.c Upper airway obstruction other than angioedema or hematoma

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

L. Miscellaneous

L.o Death following exposure or poisoning